Loading clinical trials...
Loading clinical trials...
Safety and Effectiveness of Pradaxa Oral Pellet Formulation for Treatment of Acute Venous Thromboembolic Events (VTE) and/or for Risk Reduction of Recurrence of VTE in Pediatric Patients Aged 3 Months to Less Than 12 Years in a Real World Setting: a Prospective Non-interventional Study Conducted in the United States
Conditions
Locations
10
United States
University of California, San Diego
La Jolla, California, United States
Rady Children's Hospital
San Diego, California, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Johns Hopkins All Children's Hospital
St. Petersburg, Florida, United States
Indiana Hemophilia & Thrombrosis Center
Indianapolis, Indiana, United States
Cincinnati Children's Hospital
Cincinnati, Ohio, United States
Start Date
April 19, 2024
Primary Completion Date
April 28, 2025
Completion Date
April 28, 2025
Last Updated
September 4, 2025
NCT06189313
NCT07015905
NCT03728166
NCT07310693
NCT07288632
NCT06451003
Lead Sponsor
Boehringer Ingelheim
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions